Moleculin Biotech, Inc. (MBRX): R&D Expense
$15.89M
Year ended 2025-12-31
$19.68M
Trailing 12 months to 2026-06-30
-5.7%
3-year compound annual growth
+4.5%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $15.89M | -10.4% | 2026-03-18, From 2025-01-01 |
| 2024-12-31 | $17.73M | -9.0% | 2026-03-18, From 2024-01-01 |
| 2023-12-31 | $19.49M | +2.7% | 2025-03-21, From 2023-01-01 |
| 2022-12-31 | $18.97M | +31.6% | 2024-03-22, From 2022-01-01 |
| 2021-12-31 | $14.42M | +13.0% | 2023-03-22, From 2021-01-01 |
| 2020-12-31 | $12.76M | +15.8% | 2022-03-24, From 2020-01-01 |
| 2019-12-31 | $11.01M | +13.2% | 2021-03-24, From 2019-01-01 |
| 2018-12-31 | $9.73M | +114.0% | 2020-03-19, From 2018-01-01 |
| 2017-12-31 | $4.54M | +203.8% | 2019-02-21, From 2017-01-01 |
| 2016-12-31 | $1.50M | n/a | 2018-03-28, From 2016-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Moleculin Biotech, Inc. (MBRX) | 2025-12-31 | $15.89M | -10.4% |
| Abbott Laboratories (ABT) | 2025-12-31 | $2.94B | +3.4% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $9.95B | -10.8% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $13.34B | +21.3% |
| Pfizer Inc (PFE) | 2025-12-31 | $10.44B | -3.6% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $14.66B | -14.9% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $1.90M | +11.8% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $15.79B | -12.0% |
| Provectus Biopharmaceuticals, Inc. (PVCT) | 2025-12-31 | $1.90M | -7.5% |
Compare MBRX, ABT, BMY, LLY side by side · Screen every company in Pharmaceutical Preparations ↗